Bank of America’s Travere Therapeutics TVTX Stock Holding History

Bank of America’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-80,000	Closed	-$1.91M	–	8328
2025 Q3	$1.91M	Hold	80,000	–	–	﹤0.01%	4853
2025 Q2	$1.18M	Sell	80,000 -40,000	-33%	-$663K	﹤0.01%	5182
2025 Q1	$2.15M	Hold	120,000	–	–	﹤0.01%	4618
2024 Q4	$2.09M	Hold	120,000	–	–	﹤0.01%	4401
2024 Q3	$1.68M	Buy	+120,000	New	+$1.25M	﹤0.01%	4686
2018 Q3	–	Sell	-331,600	Closed	-$9.04M	–	7471
2018 Q2	$9.04M	Hold	331,600	–	–	﹤0.01%	2573
2018 Q1	$7.42M	Hold	331,600	–	–	﹤0.01%	2695
2017 Q4	$6.99M	Buy	+331,600	New	+$7.58M	﹤0.01%	2809
2015 Q3	–	Sell	-8,100	Closed	-$269K	–	7404
2015 Q2	$269K	Buy	+8,100	New	+$222K	﹤0.01%	5097

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America's TVTX Position: Q1 2026 in Review

Bank of America reduced its Travere Therapeutics (TVTX) stake by 27% in Q1 2026, selling an estimated $15.1M and leaving 1,345,111 shares worth $40M. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

Bank of America first reported a position in TVTX in Q2 2014 and has held it in 46 quarters since. The position peaked at $70.7M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Bank of America held 1,345,111 shares of Travere Therapeutics worth $40M as of Q1 2026.
Bank of America sold 505,244 Travere Therapeutics shares in Q1 2026, an estimated $15.1M.
Travere Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1771 holding.
Bank of America first reported a position in Travere Therapeutics in Q2 2014 and has held it in 46 quarters since.
Bank of America's Travere Therapeutics position peaked at $70.7M in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.